Northwest Biotherapeutics (OTCMKTS:NWBO) & NeuroBo Pharmaceuticals (NASDAQ:NRBO) Head-To-Head Review

NeuroBo Pharmaceuticals (NASDAQ:NRBO) and Northwest Biotherapeutics (OTCMKTS:NWBO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.

Earnings & Valuation

This table compares NeuroBo Pharmaceuticals and Northwest Biotherapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroBo Pharmaceuticals	N/A	N/A	-$12.47 million	N/A	N/A
Northwest Biotherapeutics	$1.93 million	212.74	-$62.60 million	($0.08)	-3.85

NeuroBo Pharmaceuticals has higher earnings, but lower revenue than Northwest Biotherapeutics.

Insider and Institutional Ownership

1.4% of NeuroBo Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Northwest Biotherapeutics shares are owned by institutional investors. 1.1% of NeuroBo Pharmaceuticals shares are owned by insiders. Comparatively, 8.7% of Northwest Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility & Risk

NeuroBo Pharmaceuticals has a beta of -0.26, meaning that its share price is 126% less volatile than the S&P 500. Comparatively, Northwest Biotherapeutics has a beta of -0.5, meaning that its share price is 150% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for NeuroBo Pharmaceuticals and Northwest Biotherapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroBo Pharmaceuticals	0	0	1	0	3.00
Northwest Biotherapeutics	0	0	0	0	0.00

NeuroBo Pharmaceuticals currently has a consensus price target of $10.00, suggesting a potential upside of 420.83%. Given NeuroBo Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts plainly believe NeuroBo Pharmaceuticals is more favorable than Northwest Biotherapeutics.

Profitability

This table compares NeuroBo Pharmaceuticals and Northwest Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeuroBo Pharmaceuticals	N/A	-189.12%	-122.31%
Northwest Biotherapeutics	-4,666.29%	N/A	-261.36%

Summary

NeuroBo Pharmaceuticals beats Northwest Biotherapeutics on 8 of the 11 factors compared between the two stocks.

About NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company’s therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.